Effects of ketamine exposure on dopamine concentrations and dopamine type 2 receptor mRNA expression in rat brain tissue

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 11181-11187

  Li, Bing ^a   Liu, Mei Li ^b   Wu, Xiu Ping ^a   Jia, Juan ^a   Cao, Jie ^a   Wei, Zhi Wen ^a   Wang, Yu Jin ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Beijing Wits Medical Consulting Co Ltd ^*  (China)

Author keywords

Abuse; Dopamine; Dopamine type 2 receptor mRNA; Ketamine; Rat brain

Indexed keywords

DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR; HOMOVANILLIC ACID; KETAMINE; MESSENGER RNA;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINE 2 RECEPTOR GENE; DOWN REGULATION; FALLING; GENE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIGHT HEMISPHERE; SUBSTANCE ABUSE;

EID: 84940688689     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Svensson TH. Dysfunction brain dopamine systems induced by psychotomimetic NMDA receptor antagonist and the effects of antipsychotic drugs. Brain Res Brain Res Rev 2000; 31: 320-329.
2. Sami BH, Erin P, Brigitte C, Christian K, Byron C, Jones BC, Cassel JC. Interactions between EtOH and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects. Psychopharmacology 2008; 197: 67-82.
3. Jin XG. Research Progress of mental side effects and neurotoxic effects of ketamine. Foreign Medicine: Anesthesiology and Resu-sciation 2003; 24: 35-38.
4. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J, Kim SY, Adhikari A, Thompson KR, Andalman AS, Gunaydin LA, Witten IB, Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013; 493: 537-41
5. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurtoxicity. Mol Psychiatry 2002; 7: 32-43
6. Irifune M, Shimizu T, Nomoto M. Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neuronsin the nucleus accumbens of mice. Pharmacol Biochem Behav 1991; 40: 399-407.
7. Meo LN, Qang JS, Fang Q, Lu YH, Zhai HF, Lu L. Ketamine Induces Rat Conditioned Place Preference. Chinese Journal of Drug Depen-dence 2006; 15: 277-279.
8. Rodríguez-Arias M, Broseta I, Aguilar MA, Miñarro J. Lack of specific effects of selective D1 and D2 dopamine antagonists vs risperidone on morphine-induced hyperactivity. Ph-armacol Biochem Behav 2000; 66: 189-197.
9. Gilles J, Rivière W, Brooks Gentry S. Michal O Disposition of MA and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 2000; 292: 1042-1047.
10. Parashchanka A, Schelfout S, Coppens M. Role of novel drugs in sedation outside the operating room: dexmedetomidine, ketamine and remifentanil. Curr Opin Anaesthesiol 2014; 27: 442-7.
11. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addi-ction 2009; 104: 1085-1099
12. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsycho-pharmacology 2000; 22: 400-412.
13. Cruickshank CC and Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104: 1085-1099.
14. Morgan CJ, Curran HV. Independent scientific committee on drugs. Ketamine use: a review. Addiction 2012; 107: 27-38.